Bristol Myers Squibb Q2 2026 Earnings: Key Takeaways for Investors
Strong Q2 Results Lead to Upgraded Full-Year Guidance
Bristol Myers Squibb (BMY) released its financial results for the second quarter of 2026, reporting robust revenue growth and significant momentum in its growth portfolio. The company has raised its full-year guidance, signaling continued confidence in both its core business and pipeline progress.
1. Key Financial Highlights
- Total Q2 Revenues: \$13.0 billion, up 6% year-over-year (5% excluding FX impacts)
- Growth Portfolio Revenues: \$7.6 billion, up 15% (14% ex-FX), now constituting a larger share of BMY’s overall business
- Legacy Portfolio Revenues: \$5.4 billion, down 4% (5% ex-FX), as expected due to generic competition
- GAAP EPS: \$1.62 per share (up from \$0.64 in Q2 2025)
- Non-GAAP EPS: \$2.04 per share (up from \$1.46 in Q2 2025)
- Net Income (GAAP): \$3.3 billion, up from \$1.3 billion
- Net Income (Non-GAAP): \$4.2 billion, up from \$3.0 billion
Product Performance
- Strong revenue growth was driven by Opdivo Qvantig (>\$200% growth), Reblozyl (+31%), Camzyos (+45%), Breyanzi (+39%), and Opdualag (+17%).
- Eliquis remains a key legacy product, with revenues up 22% worldwide.
- Revlimid and Pomalyst/Imnovid saw significant declines due to ongoing generic erosion.
- International revenues rose 6% (5% ex-FX).
2. Upgraded Full-Year 2026 Guidance – Price Sensitive
- Revenue Guidance: Increased to \$49.0 – \$50.0 billion (from prior range of \$46.0 – \$47.5 billion)
- Non-GAAP EPS: Increased to \$6.75 – \$7.00 (from \$6.05 – \$6.35)
- Operating Expenses: Now expected to be ~\$16.5 billion, reflecting increased investment in pipeline and product launches
- Worldwide Eliquis Revenue Growth: Guidance raised to 20% – 25% (prior: 10% – 15%)
Shareholder Impact: The substantial upgrade to both revenue and earnings guidance, especially the large increase in Eliquis revenue expectations, is highly price sensitive and reflects management’s strong outlook for the rest of 2026.
3. Pipeline and Regulatory Updates – Potential Value Drivers
- Reblozyl: FDA accepted a supplemental application for use with JAK inhibitors in myelofibrosis-associated anemia; PDUFA date set for March 11, 2027, supported by positive Phase 3 data.
- Mezigdomide: FDA accepted NDA in combination with carfilzomib and dexamethasone for relapsed/refractory multiple myeloma, PDUFA date May 13, 2027. Second CELMoD to receive a PDUFA date this year.
- Izalontamab brengitecan (iza-bren): Positive Phase 3 results in triple-negative breast cancer and esophageal squamous cell carcinoma, showing statistically significant and clinically meaningful improvements in survival.
- Camzyos: FDA accepted sNDA for use in adolescents with obstructive hypertrophic cardiomyopathy (based on SCOUT-HCM trial data).
- Opdivo: EC approval for combination use in Hodgkin Lymphoma (ages 12+), based on Phase 3 SWOG 1826 trial.
- Sotyktu: EC approval for use in psoriatic arthritis after positive Phase 3 data.
Shareholder Impact: Multiple late-stage regulatory milestones and positive clinical data across several key pipeline assets and indications could drive future revenue growth and support valuation upside.
4. Strategic Partnerships and Business Development – AI and Portfolio Expansion
- NVIDIA Collaboration: Expanded partnership to deploy NVIDIA’s Vera Rubin NVL72 AI infrastructure for advanced predictive modeling and clinical trial optimization.
- Anthropic Agreement: Strategic deal to deploy Claude as a shared AI platform across R&D, manufacturing, and commercial functions to accelerate innovation.
- Hengrui Pharma Collaboration: Global licensing agreements for 13 early-stage programs in oncology, hematology, and immunology, boosting BMS’s early-stage pipeline.
Shareholder Impact: These partnerships represent a significant commitment to digital transformation and early-stage innovation, which could enhance long-term productivity and portfolio value.
5. Operating Metrics and Cost Structure
- Gross Margin: 71.3% (down 120 bps YoY), reflecting product mix changes
- Selling, General & Administrative Expenses: \$1.8 billion (+7% YoY), driven by new product launches
- R&D Expenses: \$3.0 billion (+15% YoY, GAAP), reflecting purchase of a priority review voucher and higher impairment charges
- Amortization of Intangibles: Down 47%, mainly due to lower Pomalyst amortization
- Net Debt: \$31.7 billion at June 30, 2026 (down from \$34.0 billion at year-end 2025), with strong liquidity position (\$11.5 billion in cash and marketable securities)
6. Risks and Forward-Looking Statements
- Guidance excludes potential impacts from future acquisitions/divestitures and significant R&D charges not yet identified.
- BMS cites risks including pricing pressures, regulatory changes, generic competition, supply chain challenges, litigation, and risks related to digital and AI partnerships.
Conclusion
Bristol Myers Squibb delivered a strong Q2 2026 with double-digit growth in its growth portfolio and key late-stage pipeline advances. The material upgrade to revenue and EPS guidance, coupled with enhanced expectations for Eliquis, reflects management’s confidence in sustained momentum. Investors should closely monitor upcoming regulatory milestones and the impact of strategic AI partnerships and early-stage pipeline collaborations, as these developments have the potential to drive future share price appreciation.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. The information is based on publicly available data as of July 30, 2026, and may be subject to change.
